Bryan Lawlis - Geron Independent Director
| GERN Stock | USD 3.73 0.05 1.36% |
Director
Dr. V. Bryan Lawlis, Ph.D., is Independent Director of Geron Corporationration Dr. Lawlis has served as a director of Geron since March 2012. He also serves as a member of the boards of directors of BioMarin Pharmaceutical, Inc., a biopharmaceutical company specializing in rare genetic diseases, since June 2007 Coherus BioSciences, Inc., a biologics platform company specializing in biosimilars, since May 2014 Sutro Biopharma, Inc., a biologics platform company specializing in therapeutics for cancer and autoimmune disorders, since January 2004 Aeglea BioTherapeutics, Inc., a biotechnology company specializing in human enzyme therapeutics for rare genetic diseases and cancer, since July 2018 and several privatelyheld biotechnology companies. From August 2013 to September 2014, Dr. Lawlis served as a member of the board of directors of KaloBios Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Lawlis was also the President and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privatelyheld, early stage biopharmaceutical company that he cofounded, from 2006 to 2011, and has served as an advisor to Phoenix Venture Partners, a VC firm specializing in manufacturing technologies, since October 2015. Dr. Lawlis held several senior management positions in the biopharmaceutical industry, including President and Chief Executive Officer of Aradigm Corporationrationration, a specialty drug company focused on drug delivery technologies, and President and Chief Executive Officer of Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, which he cofounded since 2012.
| Age | 66 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Address | 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404 |
| Phone | 650 473 7700 |
| Web | https://www.geron.com |
Geron Management Efficiency
The company has return on total asset (ROA) of (0.4147) % which means that it has lost $0.4147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1229) %, meaning that it created substantial loss on money invested by shareholders. Geron's management efficiency ratios could be used to measure how well Geron manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to drop to -0.49. In addition to that, Return On Capital Employed is likely to drop to -0.71. At this time, Geron's Total Assets are very stable compared to the past year. As of the 18th of April 2024, Non Current Assets Total is likely to grow to about 55.4 M, while Non Currrent Assets Other are likely to drop about 4.5 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Herndon | Home Federal Bancorp | 79 | |
| John Bosen | Provident Bancorp | 49 | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Lisa DeStefano | Provident Bancorp | N/A | |
| Andres Chevallier | Betterware De Mexico | 40 | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Mari Cano | Betterware De Mexico | N/A | |
| Mark Harrison | Home Federal Bancorp | 58 | |
| Wayne Tatro | Provident Bancorp | 72 | |
| Richard Peeke | Provident Bancorp | 69 | |
| Laurie Knapp | Provident Bancorp | 56 | |
| Jay Gould | Provident Bancorp | N/A | |
| Eduardo Szymanski | Betterware De Mexico | N/A | |
| Thomas Trawick | Home Federal Bancorp | 48 | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| Scott Lawrence | Home Federal Bancorp | 71 | |
| Frank Cousins | Provident Bancorp | 55 | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
Management Performance
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.41 |
Geron Leadership Team
Elected by the shareholders, the Geron's board of directors comprises two types of representatives: Geron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Geron. The board's role is to monitor Geron's management team and ensure that shareholders' interests are well served. Geron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Geron's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharo McBain, Vice President - Global Regulatory Affairs | ||
| Hoyoung Huh, Chairman of the Board | ||
| Dawn Bir, Independent Director | ||
| Stephen JD, Chief VP | ||
| Karin Eastham, Independent Director | ||
| Israel Gutierrez, Vice President Pharmacovigilance and Drug Safety | ||
| John MD, President Board | ||
| Michelle Robertson, CFO, VP | ||
| Aleksandra Rizo, Chief Medical Officer | ||
| Anil Kapur, Executive Officer | ||
| Edward Koval, Executive Officer | ||
| Shannon Odam, Vice President - Human Resources | ||
| John Scarlett, President CEO, Director | ||
| Melissa Behrs, Executive Vice President - Portfolio and Alliance Management | ||
| Elizabeth OFarrell, Independent Director | ||
| Scott Samuels, Chief VP | ||
| Faye MD, Executive Officer | ||
| Daniel Bradbury, Independent Director | ||
| Lynn Bodarky, Vice President - Business Development | ||
| Andrew Grethlein, Executive VP of Devel. and Technical Operations | ||
| Aron Feingold, Vice Communications | ||
| Susan Molineaux, Director | ||
| Bryan Lawlis, Independent Director | ||
| Stephen Rosenfield, Executive Vice President General Counsel and Corporate Secretary | ||
| Kevin Eng, IR Contact Officer | ||
| Olivia Bloom, CFO, Executive VP of Fin. and Treasurer | ||
| Robert Spiegel, Independent Director |
Geron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Geron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 588.06 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 67.85 % | ||||
| Number Of Shares Shorted | 46.66 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 8.64 X | ||||
| Price To Sales | 9,032 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Geron Stock analysis
When running Geron's price analysis, check to measure Geron's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Geron is operating at the current time. Most of Geron's value examination focuses on studying past and present price action to predict the probability of Geron's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Geron's price. Additionally, you may evaluate how the addition of Geron to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Geron's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Quarterly Revenue Growth (0.78) | Return On Assets (0.41) | Return On Equity (1.12) |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.